Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Latest Information Update: 22 Dec 2023
At a glance
- Drugs Berotralstat (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms APeX-2
- Sponsors BioCryst Pharmaceuticals
- 19 Dec 2023 According to a BioCryst Pharmaceuticals media release, the company look forward to share additional real-world evidence at upcoming medical congresses.
- 19 Dec 2023 According to a BioCryst Pharmaceuticals media release, data from this study were published in the Journal of Allergy and Clinical Immunology.
- 19 Dec 2023 Results published in a BioCryst Pharmaceuticals Media Release.